LEXICON PHARMACEUTICALS INC (LXRX) Stock News

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.

Mentions: NVO LLY SEPN

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed;...

A Preview Of Lexicon Pharmaceuticals's Earnings

Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of 36.02% and 14.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: AGEN

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Femasys (FEMY) delivered earnings and revenue surprises of -35.29% and 77.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: FEMY

What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will...

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first...

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will...

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1

The company is looking for drugs it can add to Wegovy to improve the amount of weight lost.

Mentions: LLY NVO

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and...

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will...

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3...

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth...

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025...

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)